risk
-
Rivaroxaban significantly reduces risk of stroke
In Bayer ’s double-blind phase 3, ROCKET AF trial, rivaroxaban demonstrated superiority to warfarin in reducing the risk of stroke and non-CNS systemic embolism in patients with atrial fibrillation (AF). Importantly, rates of bleeding were simi…
risk | 29 December 2010
-
High-risk, high-return R&D
Pharmaceutical companies in the Asia Pacific region are increasingly adapting their business models from the production of generic drugs towards more highrisk, high-return R&D, according to a report released by CMR International, a Thomson Reuters b…
risk | 01 November 2010
-
Cabazitaxel and prednisone reduce risk of death for mHRPC patients
Sanofi-aventis ' phase 3 TROPIC study, which was the basis for the June 2010 US FDA approval of Jevtana (cabazitaxel) injection, was published in the October 2, 2010 print edition of The Lancet in an article titled "Prednisone plus cabazitaxel or mi…
risk | 27 October 2010
-
Poor glucose control associated with cardiovascular risk
Sanofi-aventis announced the baseline results of a worldwide prospective longitudinal epidemiologic study designed to assess the predictive value of risk factors for developing cardiovascular disease and Type 2 diabetes – INSPIRE-ME IAA (INternati…
risk | 12 October 2010
-
China: rivalry, risk and reward in the generics market
The future looks bright for drug makers who can intelligently exploit growth opportunities in China.
risk | 01 October 2010
-
Rivaroxaban shows risk reduction of DVT
Bayer announces that a novel, convenient single-drug treatment approach with oral rivaroxaban met the primary efficacy endpoint of non-inferiority in the Einstein-DVT phase three clinical trial. It showed an overall relative risk reduction compared …
risk | 16 August 2010
-
Genetic Technologies Acquires Beast Cancer Risk Test
Genetic Technologies has acquired certain assets from US-based Perlegen Sciences, with the main asset being the BrevaGen breast cancer risk test. In addition to the test, GTG has acquired a suite of granted patents that are valid to 2022 which augmen…
risk | 19 April 2010
-
Drug Packaging: Closed IV Systems to Lower Costs and Infection Risk
To address the risk of nosocomial infections in hospitals, the closed intravenous (IV) system offers a safe and effective means of packaging and delivering drug fluids.
risk | 01 May 2009
-
Cholesterol Drug Cuts Heart Risk
Data from a study presented at the American Heart Association Scientific Sessions demonstrated that Crestor (rosuvastatin calcium) reduced major cardiovascular (CV) events by 44% compared to placebo. It also reduced the combined risk of cardiovascula…
risk | 30 December 2008
-
Tests for Assessing Risk of Common Diseases
Lab21 Limited says it has entered into a partnership with deCODE genetics to offer deCODE's tests for predisposition to a growing number of common diseases. The license allows Lab21 to offer its clients in the UK and Ireland access to new tests for …
risk | 01 September 2008
